Maxim Group analyst Michael Okunewitch maintained a Buy rating on Alzamend Neuro (ALZN – Research Report) today and set a price target of $1.50. The company’s shares closed yesterday at $0.56.
Okunewitch covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, BioRestorative Therapies, and Longeveron. According to TipRanks, Okunewitch has an average return of -13.7% and a 37.93% success rate on recommended stocks.
Currently, the analyst consensus on Alzamend Neuro is a Moderate Buy with an average price target of $4.13.
See the top stocks recommended by analysts >>
Based on Alzamend Neuro’s latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $5.43 million. In comparison, last year the company had a GAAP net loss of $2.57 million
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALZN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s.
Read More on ALZN:
